Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis

Summary

This pilot study is being done to see if the study medication, Rituximab, preserves kidney function after 12 months of taking the drug.

Timeline

Start

2014-11

Primary completion

2017-04

Completion

2017-04

Outcome

Missed primary endpoint

paper The creatinine clearance did not change significantly during this time, from 47.7 mL/min/1.73 m2 at baseline to 43.7 mL/min/1.73 m2 during follow-up (P = 0.15). PMID 32617582 ↗

Publications

• Erickson SB, Zand L, Nasr SH, Alexander MP, Leung N, Drosou ME, Fervenza FC. Treatment of fibrillary glomerulonephritis with rituximab: a 12-month pilot study. Nephrol Dial Transplant. 2021 Jan 1;36(1):104-110. doi: 10.1093/ndt/gfaa065.

Drugs

Indications